Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.

Cancer science - 1 Sept 2021

Wang Zaozao, Kang Bin, Gao Qianqian, Huang Lei, Di Jiabo, Fan Yingcong, Yu Jianhong, Jiang Beihai, Gao Feng, Wang Dan, Sun Haixi, Gu Ying, Li Jian, Su Xiangqian

Abstract excerpt

Mutated KRAS promotes the activation of the MAPK pathway and the progression of colorectal cancer (CRC) cells. Aberrant activation of the PI3K pathway strongly attenuates the efficacy of MAPK suppression in KRAS-mutated CRC. The development of a novel strategy targeting a dual pathway is therefore highly essential for the therapy of KRAS-mutated CRC. In this study, a quadruple-depleting system for the KRAS, MEK1,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Gene Editing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HCT116 Cells

Share to MAP Kinase Kinase 1

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to TOR Serine-Threonine Kinases

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 34185934
DOI: 10.1111/cas.15049
PMCID: PMC8409416

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.PMID 34185934Read ↗

Quadruple-editing of MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cellsSemantic proximity Read ↗

Selective targeting of an oncogenic <i>KRAS</i> mutant allele by CRISPR/Cas9 induces efficient tumor regressionSemantic proximity Read ↗

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.Semantic proximity Read ↗

Reovirus sensitizes microsatellite stable colorectal cancer to anti-PD-1 treatment via cross-talk in innate and adaptive immune systemsSemantic proximity Read ↗

CRISPR prime editing for unconstrained correction of oncogenic KRAS variants.Semantic proximity Read ↗

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancerSemantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth.Semantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.Semantic proximity Read ↗

Cancer modeling in colorectal organoids reveals intrinsic differences between oncogenic <i>RAS</i> and <i>BRAF</i> variantsSemantic proximity Read ↗

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.